| Class 514 | DRUG, BIO-AFFECTING AND BODY TREATING COMPOSITIONS |
| Click here for a printable version of this file | |
Expand/Contract Processing Please Wait
| This Class 514 is considered to be an integral part of Class 424 (see the Class 424 schedule for the position of this Class in schedule hierarchy). This Class retains all pertinent definitions and class lines of Class 424. | ||
![[List of Pre Grant Publications for class 514 subclass 1]](../as.gif) | ![[List of Patents for class 514 subclass 1]](../ps.gif) | 1 | DESIGNATED ORGANIC ACTIVE INGREDIENT CONTAINING (DOAI) |
| | 1.1 |  Peptide (e.g., protein, etc.) containing DOAI |
| | 1.2 |  Transporter affecting or utilizing |
| | 1.3 | Prodrug utilizing |
| | 1.4 | Sepsis affecting |
| | 1.5 | Respiratory distress syndrome (e.g., ARDS, IRDS, etc.) affecting |
| | 1.6 | Pneumonia affecting |
| | 1.7 | Asthma affecting |
| | 1.8 | Cystic fibrosis affecting |
| | 1.9 | Arteriosclerosis (e.g., atherosclerosis, etc.) affecting |
| | 2.1 | Endotoxin (e.g., LPS, etc.) affecting |
| | 2.2 | Bactericidal/permeability-increasing (BPI) protein affecting or utilizing |
| | 2.3 | Micro-organism destroying or inhibiting |
| | 2.4 |  Bacterium (e.g., Bacillus, etc.) destroying or inhibiting |
| | 2.5 |  Lactoferrin |
| | 2.6 | Streptococcus |
| | 2.7 | Staphylococcus (e.g., Staphylococcus aureus, etc.) |
| | 2.8 | Gram negative bacterium (e.g., Escherichia coli, salmonella, Helicobacter, etc.) |
| | 2.9 | Cyclopeptide utilizing |
| | 3.1 | Glycopeptide utilizing |
| | 3.2 | Amphiphilic or oligomer modified peptide (e.g., magainin, peptide nucleic acid, or PEGylated peptide, etc.) utilizing |
| | 3.3 | Fungus (e.g., athlete's foot, ringworm, etc.) destroying or inhibiting |
| | 3.7 | Virus destroying or inhibiting |
| | 3.8 | Human immunodeficiency virus (HIV) |
| | 3.9 |  Cluster of differentiation protein (e.g., CD4, etc.) affecting |
| | 4.1 | HIV protease inhibitor affecting or utilizing |
| | 4.2 | Herpesviridae |
| | 4.3 | Hepatitis |
| | 4.4 | Protozoa destroying or inhibiting |
| | 4.5 | Insect destroying or inhibiting |
| | 4.6 | Parasite (e.g., tapeworm, roundworm, nematode, etc.) destroying or inhibiting |
| | 4.7 | Lactation affecting |
| | 4.8 | Weight regulation affecting |
| | 4.9 | Appetite or satiation affecting |
| | 5.1 | Growth hormone (GH) or derivative utilizing |
| | 5.2 | Neuropeptide (e.g., NPY, PYY, dynorphin, etc.) or derivative utilizing |
| | 5.3 | Peptide hormone or derivative utilizing |
| | 5.4 | Iron affecting |
| | 5.5 | Nutrition enhancement or support |
| | 5.8 | Leptin or derivative affecting or utilizing |
| | 5.9 | Insulin or derivative utilizing |
| | 6.1 | Truncated insulin |
| | 6.2 | A-chain modified insulin |
| | 6.3 | B-chain modified insulin |
| | 6.4 | Zinc containing |
| | 6.5 | With an additional active ingredient |
| | 6.7 | Insulin affecting |
| | 6.8 | Blood sugar affecting |
| | 7.4 | Lipid or cholesterol affecting (e.g., dyslipidemia, etc.) |
| | 7.5 | Protein tyrosine kinase (PTK) affecting |
| | 7.6 | Growth factor or derivative affecting or utilizing |
| | 7.7 | Erythropoietin (EPO) or derivative |
| | 7.8 | Thrombopoietin (TPO) or derivative |
| | 7.9 | Hematopoiesis affecting |
| | 8.1 | Vascular endothelial growth factor (e.g., VEGF-A, VEGF-B, etc.) or derivative |
| | 8.2 | Platelet-derived growth factor (PDGF) or derivative |
| | 8.3 | Nerve tissue or nerve cell growth affecting |
| | 8.5 | Insulin-like growth factor (IGF) or derivative |
| | 8.6 | Insulin-like growth factor 1 (IGF-1) or derivative |
| | 8.7 | Insulin-like growth factor binding protein (IGFBP) or derivative |
| | 8.8 | Bone morphogenic protein (BMP) or derivative |
| | 8.9 | Transforming growth factor (TGF) or derivative |
| | 9.1 | Fibroblast growth factor (FGF) or derivative |
| | 9.3 | Fibronectin or derivative |
| | 9.4 | Wound healing or wound repair affecting |
| | 9.5 | Hepatocyte growth factor (HGF) or derivative |
| | 9.6 | Epidermal growth factor (EGF) or epidermal growth factor-like or derivative |
| | 9.7 | Hormone or derivative affecting or utilizing |
| | 9.8 | Fertility |
| | 9.9 | Follicle-stimulating hormone (FSH) or derivative |
| | 10.1 | Luteinizing hormone (LH) or derivative |
| | 10.2 | Androgen (e.g., testosterone, etc.) or estrogen affecting |
| | 10.3 | Gonadotropin-releasing hormone (GnRH) or derivative |
| | 10.7 | Melanocortin (e.g., Melanocyte-stimulating hormone (MSH), etc.) or derivative |
| | 10.9 | Vasopressin or derivative |
| | 11.1 | Somatostatin or derivative |
| | 11.2 | Growth-hormone-releasing hormone (GHRH) or derivative |
| | 11.3 | Growth hormone (GH) or derivative |
| | 11.5 | Prolactin or derivative |
| | 11.6 | Oxytocin or derivative |
| | 11.7 | Glucagon, glucagon-like peptide (e.g., GLP-1, GLP-2, etc.) or derivative |
| | 11.8 | Parathyroid hormone (PTH) or derivative |
| | 11.9 | Calcitonin or derivative |
| | 12.1 | Muscle contraction affecting (e.g., muscle twitch, muscle relaxation, etc.) |
| | 12.2 | Anti-inflammatory |
| | 12.3 | Gastrin hormone or derivative |
| | 12.4 | Natriuretic peptide or derivative (e.g., atrial natriuretic peptide, brain natriuretic peptide, etc.) |
| | 12.5 | Bradykinin or derivative |
| | 12.6 | Cholecystokinin (CCK) or derivative |
| | 12.7 | Relaxin or derivative |
| | 12.8 | Secretin or derivative |
| | 12.9 | Thymosin (e.g., thymosin (alpha 1, thymosin beta 4, etc.) or derivative |
| | 13.1 | Vasoactive intestinal peptide (VIP) or derivative |
| | 13.2 | Digestive tract ulcer affecting |
| | 13.3 | Angiogenesis affecting |
| | 13.4 | Blood substitute |
| | 13.5 | Blood affecting or blood protein utilizing |
| | 13.6 | Fibrin or derivative affecting or utilizing |
| | 13.7 | Coagulation affecting |
| | 13.8 | Platelet aggregation or adhesion affecting |
| | 14.1 | Factor VIII or derivative affecting or utilizing |
| | 14.2 | Plasma protease affecting |
| | 14.3 | Factor VIIa affecting |
| | 14.4 | Factor Xa affecting |
| | 14.6 | Urokinase affecting |
| | 14.7 | Thrombin affecting |
| | 14.9 | Thrombosis affecting |
| | 15.1 | Oxidative stress affecting |
| | 15.2 | Albumin or derivative affecting or utilizing |
| | 15.3 | Plasma protein affecting or utilizing |
| | 15.4 | Kidney affecting |
| | 15.5 | Surfactant protein (e.g., SP-A, SP-B, etc.) or derivative affecting or utilizing |
| | 15.6 | Blood pressure affecting |
| | 16.3 | Angiotensin converting enzyme (ACE) affecting |
| | 16.4 | Cardiac disease (i.e., heart disease) affecting |
| | 16.5 | Tissue development affecting |
| | 16.6 | Rheumatoid arthritis affecting |
| | 16.7 | Bone affecting |
| | 17.1 | Cartilage affecting |
| | 17.2 | Collagen or derivative affecting or utilizing |
| | 17.3 | N-methyl-d-aspartate (NMDA) receptor affecting |
| | 17.4 | Ion channel protein affecting |
| | 17.5 | Mental disorder or mental illness (e.g., psychoses, etc.) affecting |
| | 17.7 | Nervous system (e.g., central nervous system (CNS), etc.) affecting |
| | 17.8 | Alzheimer's disease |
| | 17.9 | Multiple sclerosis |
| | 18.1 | Neurotransmitter or derivative affecting or utilizing |
| | 18.2 | Neuropathy affecting |
| | 18.3 | Pain affecting |
| | 18.6 | Skin affecting |
| | 18.9 | Apoptosis affecting |
| | 19.1 | Cellular adhesion affecting or cell adhesion molecule (CAM) affecting or utilizing |
| | 19.2 | Neoplastic condition affecting |
| | 20.1 | Protease inhibitor affecting or utilizing |
| | 20.2 | Cysteine protease inhibitor affecting or utilizing |
| | 20.3 | Serine protease inhibitor affecting or utilizing |
| | 20.5 | Cyclosporine or derivative utilizing |
| | 20.6 | G-protein coupled receptor (GPCR) affecting |
| | 20.7 | Hair affecting |
| | 20.8 | Eye affecting |
| | 20.9 | Glycopeptide utilizing |
| | 21.1 | Cyclopeptide utilizing |
| | 21.2 | 100 or more amino acid residues in the peptide chain |
| | 21.3 | 25 to 99 amino acid residues in the peptide chain |
| | 21.4 | 16 to 24 amino acid residues in the peptide chain |
| | 21.5 | 12 to 15 amino acid residues in the peptide chain |
| | 21.6 | 9 to 11 amino acid residues in the peptide chain |
| | 21.7 | 7 or 8 amino acid residues in the peptide chain |
| | 21.8 | 5 or 6 amino acid residues in the peptide chain |
| | 21.9 | 3 or 4 amino acid residues in the peptide chain |
| | 21.91 | 2 amino acid residues in the peptide chain |
| | 21.92 | Produced by or extracted from animal tissue |
| | 22 | Lignin or derivative DOAI |
| | 23 | Carbohydrate (i.e., saccharide radical containing) DOAI |
| | 24 | S-glycoside |
| | 25 | O-glycoside |
| | 26 | Cyclopentanohydrophenanthrene ring system |
| | 27 | Oxygen of the saccharide radical bonded directly to a nonsaccharide hetero ring or a polycyclo ring system which contains a nonsaccharide hetero ring |
| | 32 | Oxygen of the saccharide radical bonded to a nonsaccharide hetero ring by acyclic carbon bonding |
| | 33 | Oxygen of the saccharide radical bonded directly to a polycyclo ring system of three or more carbocyclic rings |
| | 34 | Oxygen of the saccharide radical bonded directly to a polycyclo ring system of four carbocyclic rings (e.g., daunomycin, etc.) |
| | 35 | Oxygen of the saccharide radical bonded directly to a cyclohexyl ring |
| | 36 | Two or more nitrogen atoms bonded directly to the cyclohexyl ring |
| | 42 | N-glycoside |
| | 43 | Nitrogen containing hetero ring |
| | 53 | Dissacharide |
| | 54 | Polysaccharide |
| | 55 | Chitin or derivative |
| | 56 | Heparin or derivative |
| | 57 | Cellulose or derivative |
| | 58 | Dextrin or derivative |
| | 59 | Dextran or derivative |
| | 60 | Starch or derivative |
| | 61 | Tri- or tetrasaccharide |
| | 62 | Glucosamine or derivative |
| | 63 | Silicon containing DOAI |
| | 64 | Boron containing DOAI |
| | 65 | Pyrethrum plant derived material or plant derived rotenone compound containing DOAI |
| | 66 | With heterocyclic compound |
| | 68 | With carboxylic acid ester |
| | 69 | With carboxylic acid metal salt |
| | 70 | With organic nitrogen containing compound |
| | 72 | With organic oxygen containing compound |
| | 74 | With hydrocarbon or halohydrocarbon |
| | 75 | Phosphorus containing other than solely as part of an inorganic ion in an addition salt DOAI |
| | 76 | Amine addition salt of organic phosphorus containing acid |
| | 77 | Inner salt (e.g., betaine, etc.) |
| | 79 | Nitrogen containing hetero ring |
| | 80 | Polycylo ring system having a ring nitrogen in the system |
| | 81 | Nonshared hetero atoms in at least two rings of the polycyclo ring system |
| | 82 | Quinolinyl or isoquinolinyl (including hydrogenated) |
| | 83 | Hetero ring is three-membered consisting of one nitrogen and two carbons |
| | 84 | Hetero ring is six-membered consisting of three nitrogens and three carbons |
| | 85 | Hetero ring is six-membered consisting of two nitrogens and four carbons |
| | 89 | Hetero ring is six-membered and includes only one ring nitrogen |
| | 91 | Hetero ring is five-membered |
| | 95 | Sulfur containing hetero ring |
| | 96 | Polycyclo ring system having the hetero ring as one of the cyclos |
| | 97 | Two or more sulfurs in the hetero ring |
| | 98 | Oxygen in the hetero ring |
| | 99 | Oxygen containing hetero ring |
| | 100 | Polycyclo ring system having the hetero ring as one of the cyclos |
| | 101 | Two or more oxygen in the hetero ring |
| | 102 | Two or more phosphorus atoms directly or indirectly bonded together by only covalent bonds |
| | 103 | Phosphorus acid ester of polyhydric alcohol or thioalcohol (e.g., P-X-R-X-P group, etc., wherein X is chalcogen and R is the residue of the polyhydric alcohol or thioalcohol) |
| | 105 | Phosphorus is part of a ring |
| | 106 | P-O-P or P-S-P containing (e.g., anhydrides, etc.) |
| | 107 | Benzene ring containing |
| | 108 | Acyclic and contains at least one carbon atom between the phosphorus atoms |
| | 109 | P-X-X containing (X is chalcogen) |
| | 110 | Phosphorus is part of a ring |
| | 112 | Cyano or isocyano containing |
| | 114 | Nitrogen, other than nitro or nitroso, bonded indirectly to phosphorus |
| | 115 | N-C(=X)-N containing (X is chalcogen) |
| | 116 | Sulfur single bonded directly to nitrogen |
| | 118 | Phosphorus single bonded directly to nitrogen |
| | 119 | C(=O)N containing |
| | 120 | C=O other than as ketone or aldehyde, attached directly or indirectly to phosphorus |
| | 121 | Plural C=O groups, other than as ketone or aldehyde |
| | 124 | C=O, other than as ketone or aldehyde, attached to a benzene ring |
| | 125 | Ketone or aldehyde containing |
| | 126 | Sulfur not bonded directly to phosphorus |
| | 129 | Oxygen bonded directly to a carbon or hydrogen and wherein the oxygen is not bonded directly to phosphorus |
| | 131 | Nitro group bonded to a carbon |
| | 132 | Nitro group is directly bonded to a benzene ring which benzene ring is either bonded directly bonded to phosphorus or indirectly bonded to phosphorus through a chalcogen |
| | 134 | Acyclic carbon to carbon unsaturation |
| | 137 | Nitrogen bonded directly to phosphorus |
| | 139 | Phosphorus bonded directly to halogen |
| | 140 | (C)(R)P=X(-XC) containing (i.e., Phosphinate (X is chalcogen; R is C or H) |
| | 141 | (CX-) (C)P=X(XH) or (CX-) (R)P=X(XC) containing (e.g., phosphonate, etc.) (X is chalcogen; R is C or H) |
| | 142 | (CX-)(C)P(C),(CX-)(RX-)P(C),(CX-)P(XH)(XH) or (CX-)(CX-)P(-XR) containing (X is chalcogen; R is C or H) (e.g., phosphinite, phosphite, etc.) |
| | 143 | Ester of (HX)P=X(XH)(XH) (X is chalcogen) (e.g., phosphate, etc.) |
| | 149 | Azoxy DOAI |
| | 150 | Acyclic nitrogen double bonded to acyclic nitrogen, acyclic nitrogen triple bonded to acyclic nitrogen or azide DOAI |
| | 152 | 3,10-dihydroxy-2-naphthacene carboxamide or derivative (e.g., tetracycline, etc.) DOAI |
| | 153 | With stabilizer or preservative |
| | 154 | With an additional active ingredient (excludes reaction product or complex) |
| | 155 | Para-N-benzene - sulfoxy-N containing DOAI, and said benzene ring is not part of a polycyclo ring system |
| | 159 | Ortho-hydroxybenzoic acid (i.e., salicyclic acid) or derivative DOAI |
| | 160 | With additional ortho-hydroxybenzoic acid compound |
| | 161 | With heterocyclic compound |
| | 162 | With organic nitrogen containing compound |
| | 163 | With carboxylic acid, ester or metal salt thereof |
| | 164 | With organic oxygen containing compound |
| | 165 | Aspirin per se (i.e., 2-(acetyloxy)benozic acid) |
| | 166 | Nitrogen containing (e.g., anilides, etc.) |
| | 167 | 9,10-seco- cyclopentanohydrophenanthrene ring system (e.g., vitamin D, etc.) DOAI |
| | 169 | Cyclopentanohydrophenanthrene ring system DOAI |
| | 170 | Plural Compounds containing cyclopentanohydrophenanthrene ring systems |
| | 171 | With additional active ingredient |
| | 172 | Hetero ring containing |
| | 173 | Spiro ring system |
| | 174 | -O-C-O- is part of a hetero ring (e.g., acetonide, etc.) |
| | 175 | -C(=O)-O-is part of a hetero ring (e.g., lactone, etc.) |
| | 176 | Nitrogen containing hetero ring |
| | 177 | Oxygen double bonded to a ring carbon of the cyclopentanohydrophenanthrene ring system |
| | 182 | Oxygen single bonded to a ring carbon of the cyclopentanohydrophenanthrene ring system |
| | 183 | Heterocyclic carbon compounds containing a hetero ring having chalcogen (i.e., O,S,Se or Te) or nitrogen as the only ring hetero atoms DOAI |
| | 184 | Heavy metal containing (including salts) |
| | 185 | Polycyclo ring system |
| | 188 | Hetero ring is six-membered consisting of one nitrogen and five carbons |
| | 189 | Tin |
| | 190 | Mercury |
| | 191 | Aluminum (including salts) |
| | 192 | 1-thia-4-aza-bicyclo (3.2.0) heptane ring containing (including dehydrogenated) (e.g., penicillins, etc.) |
| | 193 | Spiro or additional polycyclo ring system |
| | 194 | 6,6-di-substituted |
| | 195 | 3-position substituent contains -COOC- group |
| | 196 | 6-position substituent contains hetero ring |
| | 197 | 6-position substituent contains carbocyclic ring |
| | 200 | 1-thia-5-aza-bicyclo (4.2.0) octane ring containing (including dehydrogenated) (e.g., cephalosporins, etc.) |
| | 201 | 7,7-di-substituted |
| | 202 | Additional hetero ring |
| | 203 | 3-position substituent contains pyridine ring |
| | 204 | 3-position substituent contains sulfur |
| | 205 | The additional hetero ring is part of a polycyclo ring system |
| | 206 | 7-position substituent contains hetero ring |
| | 207 | Alkyl, hydroxyalkyl, alkoxyalkyl or alkanoyloxyakyl bonded directly to 3-position |
| | 208 | Sulfur containing substituent |
| | 209 | Alkyl, hydroxyalkyl, alkoxyalkyl, or alkanoyloxyakyl bonded directly to 3-position |
| | 210.01 | Hetero ring is four-membered and includes at least one ring nitrogen |
| | 210.02 | Chalcogen double bonded directly to a ring carbon of the four-membered hetero ring which is adjacent to the ring nitrogen |
| | 210.03 | Polycyclo ring system having the four-membered hetero ring as one of the cyclos |
| | 210.04 | Bicyclo ring system having the four-membered hetero ring as one of the cyclos |
| | 210.05 |  Plural ring hetero atoms in the bicyclo ring system |
| | 210.09 | The other cyclo of the bicyclo ring system is five-membered |
| | 210.15 | Chalcogen bonded directly to the ring nitrogen of the four-membered ring |
| | 210.16 | Polycyclo ring system having the four-membered hetero ring as one of the cyclos |
| | 210.17 | Having -C(=X)-, wherein X is chalcogen, bonded directly to the four-membered hetero ring |
| | 210.18 | Additional hetero ring attached directly or indirectly to the four-membered hetero ring by nonionic bonding |
| | 210.19 | Additional hetero ring attached directly or indirectly to the four-membered hetero ring by nonionic bonding |
| | 211.01 | Hetero ring contains seven members including nitrogen, carbon and chalcogen |
| | 211.02 | Monocyclic cyclopentyl ring bonded directly to the seven-membered hetero ring (e.g., prostaglandins, etc.) |
| | 211.03 | Chalcogen double bonded directly to a ring carbon which is adjacent to the ring nitrogen |
| | 211.04 | Polycyclo ring system which contains the seven-membered hetero ring as one of the cyclos |
| | 211.08 | Plural ring nitrogens in the seven-membered hetero ring |
| | 211.09 | Polycyclo ring system which contains the seven-membered hetero ring as one of the cyclos |
| | 211.1 | Three ring hetero atoms in the polycyclo ring system |
| | 211.11 | Tricyclo ring system having the seven-mmbered hetero ring as one of the cyclos |
| | 211.15 | Additional nitrogen containing hetero ring attached directly or indirectly to the seven-membered hetero ring by nonionic bonding |
| | 212.01 | Hetero ring is seven-membered consisting of one nitrogen and six carbons |
| | 212.02 | Spiro |
| | 212.03 | Chalcogen double bonded directly to a ring carbon of the seven-membered hetero ring which is adjacent to the ring nitrogen |
| | 212.04 | Polycyclo ring system having the seven-membered hetero ring as one of the cyclos |
| | 212.05 | Plural cyclos of the polycyclo ring system share ring nitrogen of the seven-membered hetero ring |
| | 212.06 | Plural ring hetero atoms in the polycyclo ring system |
| | 212.07 | Bicyclo ring system having the seven-membered hetero ring as one of the cyclos |
| | 212.08 | Additional hetero ring attached directly or indirectly by nonionic bonding to the seven-membered hetero ring |
| | 213.01 | Polycyclo ring system having the seven-membered hetero ring as one of the cyclos |
| | 214.01 | Ring nitrogen of the seven-membered hetero ring is shared by an additional cyclo of the polycyclo ring system |
| | 214.02 | Plural ring nitrogens in the polycyclo ring system |
| | 214.03 | Two of the cyclos share at least three ring members (i.e., bridged) |
| | 215 | Additional hetero atom in the polycyclo ring system |
| | 216 | Two of the cyclos share at least three ring carbons (i.e., bridged) |
| | 217 | Tricyclo ring system having the seven-membered hetero ring a one of the cyclos |
| | 217.01 | 3-Benzazepines (including hydrogenated) |
| | 217.03 | Additional hetero ring attached directly or indirectly to the seven-membered hetero ring by nonionic bonding |
| | 217.04 | The additional hetero ring is six-membered and contains nitrogen |
| | 217.05 | Plural ring hetero atoms in the additional hetero ring |
| | 217.07 | Polycyclo ring system having the additional six-membered hetero ring as one of the cyclos |
| | 217.08 | The additional hetero ring is five-membered and contains nitrogen |
| | 217.11 | Nitrogen or C(=X), wherein X is chalcogen, bonded directly to the seven-membered hetero ring |
| | 217.12 | Nitrogen or C(=X), wherein X is chalcogen, attached indirectly to the seven-membered hetero ring by acyclic nonionic bonding |
| | 218 | Hetero ring is seven-membered consisting of two nitrogens and five carbon atoms |
| | 222.2 | Hetero ring is six-membered and includes at least nitrogen and sulfur as ring members |
| | 222.5 | Three or more ring hetero atoms in the six-membered hetero ring |
| | 222.8 | Polycyclo ring system having the six-membered hetero ring as one of the cyclos |
| | 223.8 | 1,3,5-Thiadiazines |
| | 224.2 | Polycyclo ring system having the six-membered hetero ring as one of the cyclos (e.g., 1,3- and 1,4- benzothiazines, etc.) |
| | 224.5 | At least three cyclos in the polycyclo ring system |
| | 224.8 | Phenothiazines (including hydrogenated) |
| | 226.5 | One of the cyclos is a 1,2-thiazine (e.g.,1,2-benzothiazines, etc.) |
| | 226.8 | 1,3-Thiazines |
| | 227.5 | 1,4-Thiazines |
| | 228.8 | Hetero ring is six-membered and includes at least nitrogen and oxygen as ring hetero atoms (e.g., monocyclic 1,2- and 1,3-oxazines, etc.) |
| | 229.2 | Three or more ring hetero atoms in the six-membered hetero ring |
| | 229.5 | Polycyclo ring system having the six-membered hetero ring as one of the cyclos (e.g., maytansinoids, etc.) |
| | 229.8 | Tricyclo ring system having the six-membered hetero ring as one of the cyclos |
| | 230.5 | Bicyclo ring system having the six-membered hetero ring as one of the cyclos (e.g., 1,4-benzoxazines, etc.) |
| | 230.8 | Chalcogen bonded directly to ring carbon of 1,4-oxazine ring |
| | 231.2 | Morpholines (i.e., fully hydrogenated 1,4- oxazines) |
| | 231.5 | Additional hetero ring attached directly or indirectly to the morpholine ring by nonionic bonding |
| | 231.8 | Plural morpholine rings attached directly or indirectly to each other by nonionic bonding |
| | 232.8 | Polycyclo ring system having the additional hetero ring as one of the cyclos |
| | 233.2 | Ring nitrogen shared by two of the cyclos |
| | 233.5 | Bicyclo ring system having the additional hetero ring as one of the cyclos |
| | 235.5 | Ring nitrogen in the additional hetero ring |
| | 235.8 | Plural ring nitrogens in the additional hetero ring (e.g., imidazole, pyrazine, etc.) |
| | 236.2 |  Three or more ring hetero atoms in the additional hetero ring |
| | 236.5 | The ring nitrogens are bonded directly to each other (e.g., pyridazine, etc.) |
| | 236.8 | Ring chalcogen in the additional hetero ring (e.g., oxazole, etc.) |
| | 237.2 | The additional hetero ring is attached indirectly to the morpholine ring by an acyclic chain having a hetero atom as a chain member |
| | 237.5 | Having -C(=X)-, wherein X is chalcogen, bonded directly to the morpholine ring |
| | 237.8 | Nitrogen attached indirectly to the morpholine ring by acyclic nonionic bonding |
| | 238.2 | Chalcogen attached directly to the nitrogen by nonionic bonding |
| | 238.5 | The nitrogen is double or triple bonded directly to carbon |
| | 238.8 | Chalcogen attached indirectly to the morpholine ring by acyclic nonionic bonding |
| | 239.5 | Carbocyclic ring attached indirectly to the morpholine ring by nonionic bonding |
| | 241 | Hetero ring is six-membered consisting of three nitrogens and three carbon atoms |
| | 242 | Asymmetrical (e.g., 1,2,4-triazine, etc.) |
| | 244 | Hexamethylenetetramines |
| | 245 | Nitrogen bonded directly to ring carbon of the hetero ring |
| | 246 | Polycyclo ring system having a 1,3,5-triazine as one of the cyclos |
| | 247 | Hetero ring is six-membered consisting of two nitrogens and four carbon atoms (e.g., pyridazines, etc.) |
| | 248 | Polycyclo ring system having a 1,2- or 1,4-diazine as one of the cyclos |
| | 252.01 | 1,2 diazine attached directly or indirectly to an additional hetero ring by nonionic bonding |
| | 252.02 | The additional hetero ring is a diazine |
| | 252.03 | The additional hetero ring is six-membered consisting of one nitrogen and five carbon atoms |
| | 252.05 | The additional hetero ring is a five-membered nitrogen hetero ring |
| | 252.1 | 1,4 diazines |
| | 252.11 | Plural 1,4-diazine rings attached directly or indirectly to each other by nonionic bonding |
| | 252.12 | Piperazines (i.e., fully hydrogenated 1,4-diazines) |
| | 252.13 | Additional hetero ring attached directly or indirectly to the piperazine ring by nonionic bonding |
| | 252.14 | The additional hetero ring is a 1,3 diazine ring |
| | 252.15 | Spiro ring system containing |
| | 252.16 | Polycyclo ring system having the additional 1,3-diazine ring as one of the cyclos |
| | 252.18 | Additional six-membered hetero ring consisting of five ring carbons and one ring nitrogen attached directly or indirectly to the 1,3-diazine by nonionic bonding |
| | 252.19 | Five-membered nitrogen hetero ring attached directly or indirectly to the 1,3-diazine ring by nonionic bonding |
| | 252.2 | Oxygen hetero ring attached directly or indirectly to the 1,3-diazine ring by nonionic bonding |
| | 253.01 | The additional hetero ring is six-membered consisting of one nitrogen and five carbon atoms |
| | 253.02 | Polycyclo ring system having the additional six-membered nitrogen hetero ring as one of the cyclos |
| | 253.03 |  Tricyclo ring system having the additional six-membered nitrogen hetero ring as one of the cyclos |
| | 253.04 | Bicyclo ring having the additional six-membered nitrogen hetero ring as one of the cyclos |
| | 253.09 | Five-membered nitrogen hetero ring attached directly or indirectly to the piperazine ring by nonionic bonding |
| | 253.11 | Chalcogen hetero ring attached directly or indirectly to the piperazine ring by nonionic bonding |
| | 253.12 | Chalcogen bonded directly to ring carbon of the additional six-membered nitrogen containing hetero ring |
| | 253.13 | Having -C(=X)-, wherein X is chalcogen, bonded directly to the additional six-membered nitrogen hetero ring |
| | 254.01 | The additional hetero ring is five-membered having ring nitrogen |
| | 254.02 | The additional five-membered hetero ring also has chalcogen as a ring member |
| | 254.03 | The additional five-membered hetero ring consists of two ring carbons, two ring nitrogens, and one ring chalcogen (e.g., oxadiazolyl, thiadiazolyl, etc.) |
| | 254.04 | The additional five-membered hetero ring consists of three ring carbons, and of nitrogen and chalcogen in adjacent ring positions (e.g., isoxazolyl, isothiazolyl, etc.) |
| | 254.05 | Plural nitrogens in the additional five-membered hetero ring |
| | 254.06 | Polycyclo ring system having the plural nitrogen containing additional five-membered hetero ring as one of the cyclos |
| | 254.07 | Chalcogen hetero ring attached directly or indirectly to the piperazine ring by nonionic bonding |
| | 254.08 | Polycyclo ring system having the additional five-membered nitrogen hetero ring as one of the cyclos |
| | 254.1 | Ring oxygen in the additional hetero ring |
| | 255.01 | Nitrogen or -C(=X)-, wherein X is chalcogen, bonded directly to the piperazine ring |
| | 255.02 | Chalcogen bonded directly to a piperazine ring carbon |
| | 255.03 | Carbocyclic ring bonded directly to the piperazine ring |
| | 255.04 | Plural carbocyclic rings bonded directly to the same acyclic carbon atom which is attached directly or indirectly to the piperazine ring by nonionic bonding |
| | 255.05 | Additional hetero ring attached directly or indirectly to the 1,4-diazine ring by nonionic bonding |
| | 255.06 | Nitrogen or -C(=X)-, wherein X is chalcogen, bonded directly to ring carbon of the 1,4-diazine ring |
| | 256 | 1,3-diazines (e.g., pyrimidines, etc.) |
| | 257 | Polycyclo ring system having 1,3-diazine as one of the cyclos |
| | 258.1 | Bicyclo ring system having the 1,3-diazine as one of the cyclos |
| | 259.1 | A ring nitrogen is shared by the two cyclos of the bicyclo ring system (e.g., pyrrolo [1,2-a]pyrimidine, imidazo[1,2-a]pyrimidine, etc.) |
| | 259.2 | Ring chalcogen in the bicyclo ring system |
| | 259.3 | The shared ring nitrogen is bonded directly to a ring nitrogen of the second ring of the bicyclo ring system (e.g., pyrazolo[1,5-a]pyrimidine, etc.) |
| | 259.31 | The second ring of the bicyclo ring system is a five-membered hetero ring including three ring nitrogens (e.g., triazolo[1,5-a]pyrimidine, etc.) |
| | 259.4 | The second ring of the bicyclo ring system is six-membered, consisting of five ring carbons and the shared ring nitrogen (e.g., pyrido[1,2-a]pyrimidine, etc.) |
| | 259.41 | Additional hetero ring is attached directly or indirectly to the bicyclo ring system by nonionic bonding |
| | 259.5 | Chalcogen bonded directly to a ring carbon of the 1,3-diazine ring |
| | 260.1 | Ring chalcogen in the bicyclo ring system |
| | 261.1 | Exactly five ring nitrogens in the bicyclo ring system (e.g., triazolo[4,5-d]pyrimidine, etc.) |
| | 262.1 | Exactly four ring nitrogens in the bicyclo ring system |
| | 263.1 | Purine (including hydrogenated) |
| | 263.2 | Additional hetero ring attached directly or indirectly to the purine ring system by nonionic bonding |
| | 263.21 |  The additional hetero ring is a 1,3-diazine ring (including hydrogenated) |
| | 263.22 | The additional hetero ring is six-membered consisting of one nitrogen and five carbons |
| | 263.23 | The additional hetero ring consists of carbon and chalcogen as the only ring members |
| | 263.3 | Chalcogen bonded directly to a ring carbon of the purine ring system |
| | 263.31 | With perservative, stabilizer, or an additional active ingredient |
| | 263.32 |  Nitrogen containing hetero ring in the perservative, stabilizer, or additional active ingredient |
| | 263.33 | Chalcogen bonded directly to the 2-,6-, and 8-positions of the purine ring system |
| | 263.34 | Chalcogen bonded directly to the 2-and 6- positions of the purine ring system (e.g., theophylline, etc.) |
| | 263.35 | Nitrogen attached indirectly to the purine ring system by acyclic nonionic bonding |
| | 263.36 | Chalcogen attached indirectly to the purine ring system by acyclic nonionic bonding |
| | 263.37 | Nitrogen bonded directly to a ring carbon of the purine ring system (e.g., guanine, etc.) |
| | 263.4 | Nitrogen bonded directly to ring carbon of the purine ring system (e.g., adenine, etc.) |
| | 264.1 | The other cyclo in the bicyclo ring system is a pyridine ring (including hydrogenated) (e.g., pyrido[2,3-d]pyrimidine, etc.) |
| | 265.1 | The other cyclo in the bicyclo ring system is a pyrrole ring (including hydrogenated) (e.g., pyrrolo[3,2-d]pyrimidine, etc.) |
| | 266.1 | Quinazoline (including hydrogenated)(i.e., the second cyclo in the bicyclo ring system is an ortho-fused six-membered carbocycle) |
| | 266.2 | Additional hetero ring attached directly or indirectly to the quinazoline ring system by nonionic bonding |
| | 266.21 | The additional hetero ring is six-membered consisting of one nitrogen and five carbons |
| | 266.23 | The additional hetero ring is five-membered consisting of carbon and plural nitrogens as the only ring members |
| | 266.24 | The additional hetero ring consists of carbon and chalcogen as the only ring members |
| | 266.3 | Chalcogen bonded directly to a ring carbon of the 1,3-diazine ring of the quinazoline ring system |
| | 266.4 | Nitrogen bonded directly to ring carbon of the 1,3-diazine ring of the quinazoline ring system |
| | 267 | Tricyclo ring system having 1,3-diazine as one of the cyclos |
| | 269 | Pyrimidines with chalcogen bonded directly to a ring carbon of said pyrimidine moiety |
| | 270 | Barbituric acid or derivative (including thioanalogs) |
| | 272 | Nitrogen bonded directly to the 1,3-diazine at 2-position |
| | 274 | Chalcogen bonded directly to pyrimidine at 2-position |
| | 275 | Nitrogen bonded directly to the 1,3-diazine at 2-position by a single bond |
| | 276 | Thiamines (e.g., vitamin B1, etc.) |
| | 277 | Hetero ring is six-membered consisting of one nitrogen and five carbon atoms |
| | 278 | Spiro ring system |
| | 279 | Polycyclo ring system having the six-membered hetero ring as one of the cyclos |
| | 280 | Pentacyclo ring system having the six-membered hetero ring as one of the cyclos |
| | 281 | Two of the cyclos share at least three ring members (i.e., bridged) |
| | 282 | One of the five cyclos is five-membered and includes ring chalcogen (e.g., codeine, morphine, etc.) |
| | 283 | Ring nitrogen in the pentacyclo ring system is shared by five-membered cyclo and six-membered cyclo (e.g., vincamine, etc.) |
| | 284 | Tetracyclo ring system having the six-membered hetero ring as one of the cyclos |
| | 285 | Plural hetero atoms in the tetracyclo ring system (e.g., acronycines, etc.) |
| | 286 | Two of the cyclos share at least three ring members (i.e., bridged) |
| | 287 | Three or more hetero atoms in the tetracyclo ring system |
| | 288 | Ring carbon is shared by three of the cyclos |
| | 289 | Two of the cyclos share at least three ring members (i.e., bridged) (e.g., morphinans, etc.) |
| | 290 | Tricyclo ring system having the six-membered hetero ring as one of the cyclos |
| | 291 | Plural hetero atoms in the tricyclo ring system |
| | 294 | Ring nitrogen is shared by two of the cyclos |
| | 295 | Two of the cyclos share at least three ring carbons (i.e., bridged) (e.g., benzomorphans, etc.) |
| | 296 | Ring carbons shared by each of the three cyclos (e.g., 1,8-naphthalimides, etc.) |
| | 297 | Acridines (including hydrogenated) |
| | 298 | Phenanthridines (including hydrogenated) |
| | 299 | Bicyclo ring system having the six-membered hetero ring as one of the cyclos |
| | 300 | Plural hetero atoms in the bicyclo ring system |
| | 301 | Ring sulfur in the bicyclo ring system |
| | 302 | Ring oxygen in the bicyclo ring system |
| | 303 | Exactly three ring nitrogens in the bicyclo ring system |
| | 304 | Tropanes (including nor or dehydro form) |
| | 305 | Quinuclidines (including unsaturation) |
| | 306 | Quinolizines (including hydrogenated) |
| | 307 | Isoquinolines (including hydrogenated) |
| | 308 | Plural isoquinoline ring systems attached directly or indirectly to each other by nonionic bonding |
| | 309 | Chalcogen attached directly to the six-membered hetero ring by nonionic bonding |
| | 310 | Nitrogen, other than as nitro or nitroso, attached directly to the isoquinoline ring system by nonionic bonding |
| | 311 | Quinolines (including hydrogenated) |
| | 312 | Chalcogen attached directly to the six-membered hetero ring by nonionic bonding |
| | 313 | Nitrogen, other than as nitro or nitroso, attached directly to the six membered hetero ring by nonionic bonding |
| | 314 | Additional hetero ring attached directly or indirectly to the quinoline ring system by nonionic bonding |
| | 315 | Piperidines |
| | 316 | Plural piperidine rings |
| | 317 | Additional ring containing |
| | 318 | The additional ring is a six-membered hetero ring consisting of one nitrogen and five carbon atoms |
| | 319 | The additional ring is one of the cyclos in a polycyclo ring system |
| | 320 | Hetero ring in the polycyclo ring system |
| | 321 | Plural hetero atoms in the polycyclo ring system |
| | 323 | Ring nitrogen in the polycyclo ring system |
| | 324 | Ring sulfur in the polycyclo ring system |
| | 325 | Polycyclo ring system is tricyclo-carbocyclic |
| | 326 | The additional ring is a hetero ring |
| | 327 | Chalcogen bonded directly to ring carbon of the piperidine ring |
| | 329 | Nitrogen attached directly to the piperidine ring by nonionic bonding |
| | 330 | C=X bonded directly to the piperidine ring (X is chalcogen) |
| | 331 | Nitrogen attached indirectly to the piperidine ring by nonionic bonding |
| | 332 | Plural six-membered hetero rings consisting of one nitrogen and five carbon atoms |
| | 333 | Additional hetero ring other than the six-membered hetero rings |
| | 334 | The six-membered hetero rings are bonded directly to each other |
| | 335 | Chalcogen bonded directly to a ring carbon of the six-membered hetero ring |
| | 336 | Additional hetero ring containing |
| | 337 | The additional hetero ring is one of the cyclos in a polycyclo ring system |
| | 340 | Ring nitrogen in the additional hetero ring (e.g., oxazole, etc.) |
| | 344 | Cyano bonded directly to the six-membered hetero ring |
| | 345 | Chalcogen bonded directly to ring carbon of the six-membered hetero ring |
| | 346 | Chalcogen and acyclic nitrogen bonded directly to the same carbon |
| | 347 | Chalcogen bonded directly to chalcogen |
| | 348 | Chalcogens bonded directly to at least two ring carbons of the six-membered hetero ring |
| | 349 | Nitrogen attached directly to the six-membered hetero ring by nonionic bonding |
| | 350 | C=O bonded directly to the six-membered hetero ring |
| | 351 | Nitrogen attached indirectly to the six-membered hetero ring by nonionic bonding |
| | 352 | Nitrogen attached directly to the six-membered hetero ring by nonionic bonding |
| | 354 | C=O bonded directly to the six-membered hetero ring |
| | 357 | Nitrogen attached indirectly to the six-membered hetero ring by nonionic bonding |
| | 358 | The ring nitrogen of the six-membered hetero ring is pentavalent (e.g., quaternary pyridinium salt, etc.) |
| | 359 | Five-membered hetero ring containing at least one nitrogen ring atom (e.g., 1,2,3-triazoles, etc.) |
| | 360 | Plural ring chalcogens in the hetero ring |
| | 361 | Plural ring nitrogens and a single chalcogen in the hetero ring |
| | 362 | 1,2,5-thiadiazoles (including hydrogenated) |
| | 363 | 1,3,4-thiadiazoles (including hydrogenated) |
| | 364 | Oxadiazoles (including hydrogenated) |
| | 365 | 1,3-thiazoles (including hydrogenated) |
| | 366 | Polycyclo ring system having the thiazole ring as one of the cyclos |
| | 369 | Chalcogen bonded directly to ring carbon of the thiazole ring |
| | 370 | Nitrogen bonded directly to ring carbon of the thiazole ring |
| | 372 | 1,2-thiazoles (including hydrogenated) |
| | 374 | 1,3-oxazoles (including hydrogenated) |
| | 375 | Polycyclo ring system having the oxazole ring as one of the cyclos |
| | 376 | Chalcogen bonded directly to ring carbon of the oxazole ring |
| | 377 | Nitrogen bonded directly to ring carbon of the oxazole ring |
| | 378 | 1,2-oxazoles (including hydrogenated) |
| | 379 | Polycyclo ring system having the oxazole ring as one of the cyclos |
| | 380 | Chalcogen or nitrogen bonded directly to ring carbon of the oxazole ring |
| | 381 | Tetrazoles (including hydrogenated) |
| | 383 | 1,2,4-triazoles (including hydrogenated) |
| | 385 | 1,3-diazoles |
| | 386 | Divalent chalcogen or acyclic nitrogen double bonded directly to ring carbon of the diazole ring, or tautomeric equivalent |
| | 387 | Polycyclo ring system having the diazole ring as one of the cyclos |
| | 389 | Divalent chalcogen or acyclic nitrogen double bonded directly at both 2- and 4- positions, or tautomeric equivalent (e.g., hydantoin, etc.) |
| | 390 | Chalcogen or nitrogen bonded directly at 1-, 3-, or 5-position by nonionic bonding |
| | 391 | Benzene ring bonded directly to the diazole ring by nonionic bonding |
| | 392 | Divalent chalcogen or acyclic nitrogen double bonded at 2-position, or tautomeric equivalent |
| | 393 | Polycyclo ring system having the diazole ring as one of the cyclos |
| | 396 | Imidazoles |
| | 397 | Additional hetero ring |
| | 398 | Chalcogen or nitrogen bonded directly to the imidazole ring by nonionic bonding |
| | 399 | Chalcogen or nitrogen bonded indirectly to the imidazole ring by nonionic bonding |
| | 401 | 2-imidazolines |
| | 403 | 1,2-diazoles |
| | 404 | Divalent chalcogen or acyclic nitrogen double bonded directly to ring carbon of the diazole ring, or tautomeric equivalent |
| | 406 | Pyrazoles |
| | 408 | The five-membered hetero ring consists of one nitrogen and four carbons |
| | 409 | Spiro ring system |
| | 410 | Polycyclo ring system having the five-membered hetero ring as one of the cyclos |
| | 411 | Tricyclo ring system having the five-membered hetero ring as one of the cyclos |
| | 412 | Bicyclo ring system having the five-membered hetero ring as one of the cyclos |
| | 413 | Ring nitrogen is shared by the cyclos of the bicyclo ring system |
| | 414 | Additional hetero ring which is not part of the bicyclo ring system |
| | 415 | The bicyclo ring system consists of the five-membered hetero ring and a benzene ring (e.g., indole, etc.) |
| | 416 | The ring nitrogen is bonded directly to nonshared ring carbons of the five-membered hetero ring (e.g., isoindole, etc.) |
| | 417 | Plural chalcogens bonded directly to ring carbons of the five-membered hetero ring (e.g., phthalimide, etc.) |
| | 418 | Chalcogen bonded directly to ring carbon of the five-membered hetero ring |
| | 419 | C=X bonded directly or indirectly by an acyclic carbon or carbon chain to ring carbon of the five-membered hetero ring (e.g., tryptophan, etc.) (X is chalcogen) |
| | 421 | Chalcogen bonded directly to ring carbon of the five-membered hetero ring (e.g., adrenochrome, etc.) |
| | 422 | Additional hetero ring |
| | 423 | C=X bonded directly to the five-membered hetero ring by nonionic bonding (X is chalcogen) |
| | 424 | Chalcogen bonded directly to the five-membered hetero ring by nonionic bonding |
| | 426 | Nitrogen bonded directly to the five-membered hetero ring by nonionic bonding |
| | 427 | Two double bonds between ring members of the five-membered hetero ring (e.g., pyrrole, etc.) |
| | 428 | Chalcogen bonded indirectly to the five-membered hetero ring by acyclic nonionic bonding |
| | 429 | Carbocyclic ring bonded directly to the five-membered hetero ring |
| | 430 | Sulfur containing hetero ring |
| | 431 | The hetero ring has at least seven members |
| | 432 | The hetero ring is six-membered |
| | 433 | Plural hetero atoms in the hetero ring |
| | 434 | Polycyclo ring system having the hetero ring as one of the cyclos |
| | 435 | Three or more hetero atoms in the hetero ring |
| | 436 | Two ring sulfurs in the hetero ring |
| | 437 | Tricyclo ring system having the hetero ring as one of the cyclos |
| | 438 | The hetero ring is five-membered |
| | 439 | Plural hetero atoms in the hetero ring |
| | 443 | Polycyclo ring system having the hetero ring as one of the cyclos |
| | 444 | Additional hetero ring |
| | 445 | Chalcogen bonded directly to ring carbon of the hetero ring |
| | 446 | Chalcogen bonded directly to ring sulfur by nonionic bonding |
| | 447 | Nitrogen bonded directly to the hetero ring |
| | 448 | C=O bonded directly to the hetero ring (X is chalcogen) |
| | 449 | Oxygen containing hetero ring |
| | 450 | The hetero ring has at least seven members |
| | 451 | The hetero ring is six-membered |
| | 452 | Plural ring oxygens in the hetero ring |
| | 453 | Polycyclo ring system having the hetero ring as one of the cyclos |
| | 454 | Tricyclo ring system having the hetero ring as one of the cyclos |
| | 456 | Bicyclo ring system having the hetero ring as one of the cyclos (e.g., chromones, etc.) |
| | 459 | Nitrogen containing |
| | 460 | Chalcogen bonded directly to ring carbon of the hetero ring |
| | 461 | The hetero ring is five-membered |
| | 462 | Spiro ring system |
| | 463 | Plural ring oxygens in the hetero ring |
| | 464 | Bicyclo ring system having the hetero ring as one of the cyclos (e.g., methylenedioxyphenyl group, etc.) |
| | 467 | Only two ring oxygens in the hetero ring which is not a polycyclo ring system (e.g., dioxolane, etc.) |
| | 468 | Polycyclo ring system having the hetero ring as one of the cyclos |
| | 471 | Nitrogen containing |
| | 473 | Chalcogen bonded directly to the hetero ring |
| | 475 | The hetero ring is three-membered |
| | 476 | N-C(=X)X containing (X is chalcogen) DOAI |
| | 477 | N-C(=X)-X-N containing |
| | 478 | N-C(=X)-X-C containing |
| | 479 | With an additional active ingredient |
| | 480 | Polycyclo ring system attached by nonionic bonding |
| | 482 | N-C(=X)-N, N-C(=N)N, N-N, nitrogen directly bonded to oxygen by nonionic bonding or cyano containing |
| | 483 | Plural N-C(=X)-X groups |
| | 484 | Ring in acid moiety |
| | 489 | Ring in alcohol moiety |
| | 491 | With an additional active ingredient |
| | 492 | Heavy metal containing DOAI |
| | 493 | Tin |
| | 494 | Zinc |
| | 495 | Gold or silver |
| | 496 | Mercury |
| | 498 | Lead |
| | 499 | Copper |
| | 501 | Nickel or cobalt |
| | 502 | Iron |
| | 503 | Antimony or bismuth |
| | 504 | Arsenic |
| | 505 | Cadmium or chromium |
| | 506 | Ester DOAI |
| | 507 | R-C(=X)-N-X-C containing (e.g., hydroxamic acid ester, etc.) (R is C or H and X is chalcogen) |
| | 508 | X-C=N containing (e.g., imidoester, etc.) (X is chalcogen) |
| | 509 | (O=)N(=O)-O-C containing (e.g., nitrate ester, etc.) |
| | 510 | Polycyclo ring system |
| | 512 | X-C(=X)-X containing (e.g., carbonic acid ester, thiocarbonic acid ester, etc.) (X is chalcogen) |
| | 513 | C-C(=X)-X-C containing (X is chalcogen and at least one X is other than oxygen) |
| | 514 | Carbon bonded to -NCX or -XCN (e.g., cyanate, thiocyanate or isothiocyanate, etc.) (X is chalcogen) |
| | 517 | S-X-C containing (e.g., sulfates, etc.) (X is chalcogen) |
| | 519 | Cyano or isocyano bonded directly to carbon |
| | 520 | Benzene ring containing |
| | 521 | C=O other than as ketone or aldehyde |
| | 523 | Additional nitrogen other than cyano |
| | 525 | Two or more of the cyano groups |
| | 526 | Acyclic |
| | 529 | Z-C(=O)-O-Y wherein Z is hydrogen or an organic radical bonded to the C(=O) by a carbon and Y is an organic radical bonded to the oxygen by a carbon |
| | 530 | Z contains a cyclopentyl or cyclopentene ring |
| | 531 | Z contains a cyclopropyl or cyclopropene ring |
| | 532 | Z-C(=O)-O-Y, wherein Z contains a benzene ring |
| | 533 | Compound contains two or more C(=O)O groups indirectly bonded together by only conalent bonds |
| | 534 | Z or Y radical contains a nitrogen atom |
| | 535 | The nitrogen of the Z radical is directly bonded to a benzene ring which is directly bonded to the C(=O) group |
| | 536 | With an agent to enhance topical absorption or with a stabilizing agent |
| | 537 | With an additional active ingredient |
| | 538 | Nitrogen bonded to carbon in Z moiety |
| | 543 | Z forms a phenoxy alkyl or phenoxy alkenyl radical |
| | 544 | C(=O)O attached directly through the carbon to a benzene ring |
| | 545 | Ketone in Z radical |
| | 546 | ZC(=O)OY, wherein Z is an acyclic radical bonded to the C=O by a carbon and Y is an organic radical bonded to the oxygen by a carbon |
| | 553 | Radical -XH acid, or anhydride, acid halide or salt thereof (X is chalcogen) DOAI |
| | 554 | Amine addition salt of the acid |
| | 556 | Inner quaternary ammonium salt (e.g., betaine, etc.) |
| | 557 | Carboxylic acid, percarboxylic acid, or salt thereof (e.g., peracetic acid, etc.) |
| | 558 | Higher fatty acid or salt thereof |
| | 561 | Nitrogen other than as nitro or nitroso nonionically bonded |
| | 562 | Sulfur nonionically bonded |
| | 563 | RC(=O)N containing (i.e., carboxamide) (R is C or H) |
| | 564 | Plural nitrogens nonionically bonded |
| | 565 | N-N or N=C(-N)-N containing (e.g., hydrazines, hydrazones, or guanidines, etc.) |
| | 566 | Polycarboxylic acid |
| | 567 | Benzene ring nonionically bonded |
| | 568 | Benzene ring nonionically bonded |
| | 572 | Cyclic carboxylic acid containing three to five carbons or cyclic percarboxylic acid containing three to five carbons or salt thereof |
| | 574 | Polycarboxylic acid or salt thereof |
| | 575 | Hydroxamic acid or salt thereof |
| | 576 | Benzene ring containing |
| | 578 | Acyclic acid or salt thereof |
| | 579 | Nitrogen containing other than solely as a nitrogen in an inorganic ion of an addition salt, a nitro or a nitroso DOAI |
| | 580 | Thioureas (i.e., N-C(=S)-N |
| | 581 | Thiocarbazides or thiosemicarbazides (i.e., N-N-C(=S)-N containing) |
| | 584 | C=O, sulfur or cyano attached directly to thiourea nitrogen by nonionic bonding |
| | 585 | Benzene ring containing |
| | 588 | Ureas (i.e., N-C(=O)-N) |
| | 589 | Nitro or nitroso bonded directly to amino nitrogen (e.g., nitramine, nitrosamine, nitro-urea, etc.) |
| | 590 | Carbazides or semicarbazides (i.e., N-N-C(=O)-N containing) |
| | 591 | Biurets (i.e., N-C(=O)-N-C(=O)-N) |
| | 592 | Sulfur attached directly to urea nitrogen by nonionic bonding |
| | 594 | Additional C=O bonded directly to urea nitrogen |
| | 595 | Benzene ring containing |
| | 599 | Thiocarboxamides, (i.e., C(=S)-N) |
| | 600 | Sulfamides (i.e., N-(O=)S(=O)-N) |
| | 601 | Sulfonamides (i.e., Q-(O=)S(=O)-N, wherein Q is a substituent and wherein any substituent attached to the nitrogen will be referred to as E) |
| | 606 | N-S-S containing |
| | 607 | N-S-N containing or contains a nitrogen bonded directly to a S=O group (e.g., sulfinamides, etc.) |
| | 608 | Sulfur attached directly to amino nitrogen by nonionic bonding (e.g., sulfenamides, etc.) |
| | 609 | Cyanamides (i.e., compounds containing cyano bonded directly to amino nitrogen) |
| | 610 | Nitramines (i.e., compounds containing nitro bonded directly to amino nitrogen) |
| | 611 | Nitrosamines (i.e., compounds containing nitroso bonded directly to amino nitrogen) |
| | 612 | Haloamines (i.e., compounds containing halogen attached directly to amino nitrogen by nonionic bonding) |
| | 613 | Carboxamides (i.e., R-C(=O)-N, wherein R is a radical having carbon bonded directly to the C(=O)-N or is hydrogen and wherein any substituent attached to nitrogen will be referred to as E) |
| | 614 | N-N containing (e.g., aminimine, hydrazine, etc.) |
| | 616 | Plural carboxamide groups or plural C=O groups bonded directly to the same nitrogen |
| | 617 | R contains benzene ring |
| | 623 | Plural alicyclic rings in R |
| | 624 | Three-membered ring in R |
| | 625 | R is acyclic |
| | 631 | Amidines (i.e., N=C-N) |
| | 632 | Amidino hydrazines or hydrazones (i.e., N-N=C-N or N=C-N-N) |
| | 633 | Amidoximes (i.e., N-C=N-O) |
| | 634 | Guanidines (i.e., N=C(-N)-N) |
| | 636 | Polyamidines |
| | 637 | Benzene ring containing |
| | 638 | Nitrogen double bonded directly to carbon |
| | 639 | Hydrazones (i.e., C=N-N) |
| | 640 | Oximes (i.e., C=N-O-) |
| | 641 | Aldimines or ketimines which contain a benzene ring (i.e., RC=N wherein R is C or H) |
| | 642 | Quaternary ammonium containing |
| | 644 | Amine oxides |
| | 645 | Nitroxides, oxyamines or hydroxylamines (i.e., N-O or N-OH) |
| | 646 | Benzene ring containing |
| | 647 | Amino nitrogen and a ring bonded directly to the same ring and any other amino nitrogen in the compound is bonded directly to one of the rings |
| | 648 | Two aryl rings or aryl ring systems bonded directly to the same acyclic carbon |
| | 649 | Amino nitrogen attached to aryl ring or aryl ring system by an acyclic carbon or acyclic chain |
| | 650 | The aryl ring or aryl ring system is bonded directly to another ring or ring system |
| | 651 | Ether oxygen is part of the chain |
| | 652 | Alkanol group only between the amino nitrogen and an ether oxygen which is bonded directly to the aryl ring or aryl ring system (i.e., aryloxy alkanol amines) |
| | 653 | Hydroxy, bonded directly to carbon, attached directly or indirectly to the acyclic carbon or chain by acyclic nonionic bonding (e.g., beta hydroxy phenethylamines, etc.) |
| | 654 | The chain consists of two or more carbons which are unsubtituted or have acyclic hydrocarbyl substituents only |
| | 656 | Polycyclo ring system |
| | 658 | Two benzene rings bonded directly to the same nitrogen |
| | 659 | Alicyclic ring or ring system and amino nitrogen are attached indirectly by an acyclic carbon or acyclic chain |
| | 660 | Plural alicyclic rings |
| | 663 | Acyclic |
| | 675 | Ketone DOAI |
| | 676 | Nitrogen containing |
| | 678 | Benzene ring containing |
| | 679 | Plural rings |
| | 688 | C=O bonded directly to benzene ring (e.g., acetophenone, etc.) |
| | 690 | Alicyclic ring containing |
| | 693 | Aldehyde DOAI |
| | 694 | Formaldehyde |
| | 698 | With preservative or stabilizer |
| | 699 | Benzene ring containing |
| | 702 | Sulfur containing |
| | 703 | Carbon to carbon unsaturation |
| | 704 | Nitrogen containing |
| | 705 | Plural C=O groups |
| | 706 | Sulfur, selenium or tellurium compound (e.g., thioalcohols, mercaptans, etc.) |
| | 707 | Persulfide (e.g., R-S-S-R, etc.) |
| | 708 | Oxygen bonded directly to sulfur (e.g., sulfoxides, etc.) |
| | 712 | Thioether |
| | 714 | Peroxide DOAI |
| | 715 | Ether DOAI |
| | 724 | C-O-group (e.g., alcohol, alcoholate, etc.) DOAI |
| | 725 | Vitamin A compound or derivative |
| | 726 | Diphenyl-substituted acyclic alcohol or alcoholate |
| | 727 | Nitrogen containing |
| | 729 | Alicyclic ring containing |
| | 730 | Benzene ring containing |
| | 738 | Polyhydroxy |
| | 739 | Carbon to carbon unsaturated |
| | 740 | Nitrogen containing compound DOAI |
| | 743 | Halogenated hydrocarbon DOAI |
| | 744 | Unsaturated aliphatic compound |
| | 747 | Carbocyclic |
| | 748 | Two benzene rings directly attached to an acyclic hydrocarbon or acyclic halogenated hydrocarbon (e.g., D.D.T., etc.) |
| | 751 | Benzene ring containing |
| | 755 | Polycyclo ring system |
| | 757 | Two or more halogenated hydrocarbons |
| | 758 | Chlorine as only halogen |
| | 759 | Fluorine as only halogen |
| | 760 | Bromine and chlorine as only halogens |
| | 761 | Bromine and fluorine as only halogens |
| | 762 | Hydrocarbon DOAI |
| | 769 | DESIGNATED INORGANIC NONACTIVE INGREDIENT OR ELEMENTAL MATERIAL OTHER THAN WATER |
| | 772 | DESIGNATED ORGANIC NONACTIVE INGREDIENT CONTAINING OTHER THAN HYDROCARBON |
| | 772.1 | Aftertreated solid synthetic organic polymer (e.g., grafting, blocking, etc.) |
| | 772.3 | Solid synthetic organic polymer |
| | 773 | Peptide containing |
| | 777 | Carbohydrate or lignin, or derivative |
| | 782 | Natural gum or resin |
| | 783 | Plant extract or plant material of undetermined constitution |
| | 784 | Carboxylic acid or salt thereof |
| | 785 | Carboxylic acid ester |
| | 788 | Nitrogen containing |
| | 788.1 | SOLID SYNTHETIC ORGANIC POLYMER DERIVED SOLELY FROM HYDROCARBON REACTANTS AS DESIGNATED ORGANIC NONACTIVE INGREDIENT CONTAINING |
| | 789 | MISCELLANEOUS (E.G., HYDROCARBONS, ETC.) |
| CROSS-REFERENCE ART COLLECTIONS | ||
| | 800 | LHRH LIKE |
| | 801 | COLLAGEN, GELATIN OR DERIVATIVES THEREOF |
| | 802 | FIBRINOPEPTIDES, BLOOD-COAGULATION FACTORS OR DERIVATIVES |
| | 803 | KININ OR DERIVATIVES |
| | 804 | PHECMYCIN SERIES OR DERIVATIVES |
| | 805 | ADRENOCORTICOTROPIC HORMONE OR DERIVATIVES |
| | 806 | SOMATOSTATIN OR DERIVATIVES |
| | 807 | OXYTOXIN, VASOPRESSIN OR DERIVATIVES |
| | 808 | CALCITONIN OR DERIVATIVES |
| | 809 | ENKEPHALIN OR ENDORPHIN OR DERIVATIVES |
| | 810 | ADDICTION |
| | 814 | ANEMIA |
| | 816 | ANESTHETIC, GENERAL |
| | 817 | ANESTHETIC, TOPICAL |
| | 818 | ANESTHETIC, LOCAL |
| | 819 | ANTACID, ORAL |
| | 821 | ANTIARRHYTHMIC |
| | 822 | ANTICOAGULATION |
| | 823 | ANTIDOTE |
| | 824 | ARTERIOSCLEROSIS |
| | 825 | ARTHRITIS |
| | 826 | ASTHMA |
| | 827 | ASTRINGENT, NONFACIAL |
| | 829 | BITE OR STING |
| | 832 | BLOOD SUBSTITUTE |
| | 833 | BLOOD PLASMA EXTENDER |
| | 834 | COAGULANT |
| | 835 | CARIES |
| | 836 | CHELATE |
| | 837 | CHOLERA |
| | 838 | CIRRHOSIS |
| | 839 | CONTACT LENS TREATMENT |
| | 841 | CONTRACEPTIVE |
| | 844 | COSMETIC, FACIAL |
| | 849 | COUGH AND COLD PREPARATION |
| | 851 | CYSTIC FIBROSIS |
| | 852 | DANDRUFF |
| | 853 | DECONGESTANT |
| DERMATITIS |
| | 858 | Athlete's foot |
| | 859 | Acne |
| | 860 | Cellulitis |
| | 861 | Eczema |
| | 862 | Poison (ivy, oak, sumac) |
| | 863 | Psoriasis |
| | 864 | Seborrhea |
| | 865 | Diaper rash |
| | 866 | DIABETES |
| | 867 | DIARRHEA |
| | 868 | DISTEMPER |
| | 869 | DIURETIC |
| | 870 | EDEMA |
| | 872 | EMESIS (MOTION SICKNESS-NAUSEA) |
| | 873 | EMOLLIENT |
| | 874 | ESTROGENIC AGENT (NONCONTRACEPTIVE) |
| | 875 | FLEA CONTROL |
| | 877 | GALLSTONE |
| | 878 | GERIATRICS |
| | 880 | HAIR TREATMENT (THERAPEUTIC-SCALP) |
| | 882 | HEMORRHOID PREPARATION |
| | 883 | HODGKIN'S DISEASE |
| | 884 | HYPOGLYCEMIA |
| | 885 | IMMUNE RESPONSE AFFECTING DRUG |
| | 886 | INFLAMMATION, SKIN |
| | 888 | INFLUENZA |
| | 889 | INTERFERON INDUCER |
| | 890 | IRRITANT (E.G., TEAR GAS, ETC.) |
| | 891 | KIDNEY STONE |
| | 892 | LAXATIVE |
| | 893 | LIVER DISORDER |
| | 895 | MALARIA |
| | 896 | MEASLES |
| | 898 | MENINGITIS |
| | 899 | MENSTRUAL DISORDER |
| MOUTH TREATMENT |
| | 903 | MULTIPLE SCLEROSIS |
| | 904 | MULTIPLE VITAMINS |
| | 906 | MUSCLE RELAXANT |
| | 907 | MUSCULAR DYSTROPHY |
| | 908 | LEUKEMIA |
| | 909 | OBESITY |
| | 912 | OPHTHALMIC |
| | 916 | PYRETIC |
| | 917 | RADIOACTIVE, ANTI- |
| | 918 | REPELLENT |
| | 921 | SHOCK |
| | 922 | SIDE EFFECT REDUCTION BY INCORPORATION OF A SECOND DESIGNATED INGREDIENT |
| | 923 | SLEEP AID (INSOMNIA) |
| | 924 | TUBERCULOSIS |
| | 925 | ULCER TREATMENT |
| | 929 | VASODILATOR |
| | 930 | VASOCONSTRICTOR (NONDECONGESTANT) |
| | 931 | VENERAL DISEASE |
| | 935 | UTERINE MOTILITY |
| LIQUID CARRIER, DILUENT OR SOLVENT |
| | 936 | DMSO CONTAINING |
| | 937 | DISPERSION OR EMULSION |
| | 944 | GEL |
| | 945 | FOAM |
| | 946 | PENETRANT OR ABSORBENT (ENHANCES PENETRATION INTO SUBJECT TREATED) |
| SOLID CARRIER OR SOLID DILUENT |
| | 948 | SOLID CANDY TYPE |
| | 949 | NATURALLY DERIVED CLAY (E.G., BENTONITE, ETC.) |
| | 950 | MACROMOLECULAR (OTHER THAN SYNTHETIC RESINS) |
| | 951 | POWDERS, GRANULES OR PARTICLES OF SPECIFIED MESH OR PARTICLE SIZE |
| | 953 | SHAPED FORMS ADAPTED FOR NONINGESTIBLE USE OTHER THAN SUPPOSITORY TYPE (E.G., FILMS, INSERTS, ETC.) |
| GASEOUS OR GAS EMITTING CARRIER OR PROPELLANT |
| | 957 | VAPOR EMMITTING COMPOSITION |
| | 958 | FOR SMOKING OR INHALING |
| | 959 | BREATHING GASES |
| PILL, LOZENGE, TABLET OR CAPSULE |
| | 960 | SIGNIFICANT, TABLET FORMULATION (E.G., DESIGNATED EXCIPIENT, DISINTEGRANT, GLYDENT OR LUBRICANT, ETC.) |
| | 962 | CAPSULE (E.G., GELATIN, ETC.) |
| | 964 | SUSTAINED OR DIFFERENTIAL RELEASE TYPE |
| SUPPOSITORY, BOUGIE OR BASE |
| | 966 | RECTAL |
| | 967 | VAGINAL |
| | 968 | URETHRAL |
| | 969 | OINTMENT OR SALVE BASE |
| SPECIAL DESIGNATED INGREDIENT |
| | 970 | CONTAINING DESIGNATED INGREDIENT TO STABILIZE AN ACTIVE INGREDIENT |
| | 971 | Crystallization point depressant or cold stabilizer containing |
| | 972 | Ultraviolet light stabilizer containing |
| | 973 | Sulfur compound additive as stabilizer (e.g., sulfites, etc.) |
| | 974 | CONTAINING DESIGNATED INGREDIENT TO REDUCE NOXIOUS EFFECTS OF ACTIVE INGREDIENT (E.G., TASTE MASKING, ODOR REDUCING, ETC.) |
| | 975 | CHARACTERIZED BY THE DESIGNATED SURFACTANT USED |
| FOREIGN ART COLLECTIONS | ||
| FOR000 | CLASS-RELATED FOREIGN DOCUMENTS |
| Any foreign patents or non-patent literature from subclasses that have been reclassified have been transferred directly to FOR Collections listed below. These Collections contain ONLY foreign patents or non-patent literature. The parenthetical references in the Collection titles refer to the abolished subclasses from which these Collections were derived. | ||
| DESIGNATED ORGANIC ACTIVE INGREDIENT CONTAINING (DOAI) |
| Heterocyclic carbon compounds containing a hetero ring having chalcogen (i.e., O,S,Se or Te) or nitrogen as the only ring hetero atoms DOAI |
| FOR104 | HETERO RING IS FOUR-MEMBERED AND INCLUDES AT LEAST ONE NITROGEN ATOM (514/210) |
| FOR105 | HETERO RING IS SEVEN-MEMBERED AND INCLUDES AT LEAST ONE NITROGEN ATOM AND AT LEAST ONE HETERO ATOM OTHER THAN NITROGEN (514/211) |
| FOR106 | HETERO RING IS SEVEN-MEMBERED CONSISTING OF ONE NITROGEN AND SIX CARBON ATOMS (514/212) |
| FOR107 | Polycyclo ring system having the seven-membered hetero ring as one of the cyclos (514/213) |
| FOR109 | Peptide containing (e.g., protein, peptones, fibrinogen, etc.) DOAI (514/2) |
| FOR110 | Insulin or derivative (514/3) |
| FOR112 | Iodine containing (514/5) |
| FOR113 | Heavy metal containing (e.g., hemoglobin, etc.) (514/6) |
| FOR114 | Phosphorus containing (514/7) |
| FOR115 | Glycoprotein (carbohydrate containing) (514/8) |
| FOR116 | Cyclopeptides (514/9) |
| FOR119 | 25 or more peptide repeating units in known peptide chain structure (514/12) |
| FOR120 | 16 to 24 peptide repeating units in known peptide chain (514/13) |
| FOR121 | 12 to 15 peptide repeating units in known peptide chain (514/14) |
| FOR122 | 9 to 11 peptide repeating units in known peptide chain (514/15) |
| FOR123 | 7 or 8 peptide repeating units in known peptide chain (514/16) |
| FOR124 | 5 or 6 peptide repeating units in known peptide chain (514/17) |
| FOR125 | 3 or 4 peptide repeating units in known peptide chain (514/18) |
| FOR126 | 2 peptide repeating units in known peptide chain (514/19) |
| FOR128 | Produced by or extracted from animal tissue (514/21) |
| DIGESTS | ||